Competition for NDA Approval Begins Before "First-in-Class" Drugs Receive Market Approval

November 5, 2015

On November 3, 2015, Tufts Center for the Study of Drug Development (CSDD) published its November/December Tufts CSDD Impact Report. According to the report, when “first-in-class” drugs receive market approval a number of follow-on products are already well into the regulatory process.

The study analyzed 40 different classes of pharmaceutical products, including both drugs and biologics from 1998 – 2011 and found:

  • 83% of all later-in-class drugs had at least initiated Phase II clinical testing abroad or in the U.S. prior to U.S. marketing approval for the first-in-class drug.
  • All later-in-class drugs had a patent filed somewhere in the world before the first-in-class drug was approved in the United States; 96% had a U.S. patent filed before first-in-class approval.
  • More than half of all later-in-class drugs received a ‘priority rating’ from the FDA.

According to the report, the race for marketing approval among these products is increasingly competitive. Jopseph DiMasi, Ph.D., Director of Economic Analysis & Research Associate Professor at Tufts CSDD, noted that the development of first-in-class drugs oftentimes begins later than that of competitive drugs in the same class.

Study results show by the time first-in-class approval is granted, the “later-in-class” products are in the following stages of development:

1998 – 2011 2005 – 2011
Phase I 66% 90%
Phase II 60% 83%
Phase III 42% 57%


Half of all later-in-class products were approved within 2.7 years of first-in-class products that were approved between 1998 and 2011. That same timeframe was reduced to 2.3 years for first-in-class products approved between 2005 and 2011.

DiMasi’s bottom line is that drug development is a “competitive race.” This race occurs “before regulatory success for any drug in the class has been established.”

Are you in the process of developing or obtaining approval for a first-in-class or later-in-class product? Using our proprietary approach, we can help you get through FDA cheaper, faster, and better. To learn more about how we can help you, please contact us.

Regulatory Sciences

September 9, 2020

Biosimilars: How the Approval Process Differs from a Standard ANDA

Biosimilars, by their very nature, are different from generic drugs. The core difference is that generic drugs are chemically synthesized, while biosimilars are grown in complex living systems....

Read the Full Article
Agency Alerts General Regulatory

April 7, 2016

Report: FDA’s Drug Review & Approval Times Reduced Drastically Since 2009

According to an infographic report from the California Life Sciences Association (CLSA), FDA approval times have decreased by nearly 50% since 2009.  The infographic, entitled “Tracking FDA Drug...

Read the Full Article
Medical Devices Agency Alerts

November 30, 2018

FDA Announces Plans to Modernize its 510(k) Medical Device Approval Process

On Monday, November 26th, FDA announced changes to modernize the 510(k) clearance pathway, which is the most common medical device submission and allows for the allows for the “clearance of low- to...

Read the Full Article